Clinical Pharmacology of Netilmicin

Open Access
Publisher Website
Google Scholar
Abstract
Pharmacological studies of netilmicin were conducted in 30 cancer patients. After intravenous administration of 50 mg of netilmicin or gentamicin per m 2 over a 1-h period in 10 patients, the mean peak serum concentrations occurred at the end of the infusion and were 7.6 and 7.3 μg/ml, respectively. At 6 h, the mean serum concentrations of both drugs was 1.1 μg/ml. After intramuscular injection of 50 mg of netilmicin per m 2 to each of the same 10 patients, the mean peak serum concentration was 5.5 μg/ml and occurred at 1 h, and, at 6 h, the mean serum concentration was 1.4 μg/ml. The mean proportion of netilmicin excreted in urine during 6 h after intramuscular injection was 55%, and after intravenous injection it was 40.9%. Results were similar with gentamicin sulfate. After administering 60 mg of netilmicin per m 2 intravenously over 30 min every 6 h in 9 patients, the mean peak serum concentration (7.9 μg/ml) occurred at the end of the infusion. The concentration gradually decreased to below 2.0 μg/ml after 4 h. Continuous infusion of 60 mg of netilmicin per m 2 every 6 h after a 60-mg/m 2 loading dose in 11 patients produced levels consistently above 2.9 μg/ml, during the initial 6-h infusion, and levels above 2.0 μg/ml for at least 1 week.